Nath: '“And lastly, we just got approval from the FDA to do a study with Checkpoint Inhibitors in Long COVID patients. The pilot study is only 10 individuals, a safety study, but nonetheless, I'm very excited about that possibility because if that works, we can actually reverse the entire...